Generation of Mice Deficient for Macrophage Galactose- and N-Acetylgalactosamine-Specific Lectin: Limited Role in Lymphoid and Erythroid Homeostasis and Evidence for Multiple Lectins

Thandi M. Onami,1,2 Meei-Yun Lin,1,2 Dawn M. Page,1,2 Shirley A. Reynolds,1,2 Carol D. Katayama,1,2 Jamey D. Marth,3,4 Tatsuro Irimura,5 Ajit Varki,6,7 Nissi Varki,6,7 and Stephen M. Hedrick1,2,*

Molecular Biology Section, Division of Biology,1 Cancer Center,2 Howard Hughes Medical Institute,3 Department of Cellular and Molecular Medicine,4 Department of Medicine,5 and Glycobiology Research and Training Center,6 University of California, San Diego, La Jolla, California 92093, and Laboratory of Cancer Biology, University of Tokyo, Tokyo 113-8657, Japan5

Received 21 March 2002/Accepted 2 April 2002

Macrophage receptors function in pattern recognition for the induction of innate immunity, in cellular communication to mediate the regulation of adaptive immune responses, and in the clearance of some glycosylated cells or glycoproteins from the circulation. They also function in homeostasis by initiating the engulfment of apoptotic cells. Evidence has suggested that macrophage receptors function to recognize cells that are destined for programmed cell death but not yet overtly apoptotic. We have examined the function of a macrophage receptor specific for unsialylated glycoproteins, known as the mouse macrophage galactose- and N-acetylgalactosamine-specific lectin (mMGL) (Ii et al., J. Biol. Chem. 265:11295-11298, 1990; Sato et al., J. Biochem. [Tokyo] 111:331-336, 1992; Yamamoto et al., Biochemistry 33:8159-8166, 1994). With targeted disruption, we tested whether mMGL is necessary for macrophage function, controlled thymic development, the loss of activated CD8 T cells, and the turnover of red blood cells. Evidence indicates that mMGL may play a nonessential role in several of these macrophage functions. Experiments are presented that indicate the existence of another galactose- and N-acetylgalactosamine-recognizing lectin distinct from mMGL. This may explain the absence of a strong phenotype in mMGL-deficient mice.

Differential sialylation is a general property of hematopoietic cell development, including lymphocytes and erythrocytes. For example, at a distinct stage in thymic development, several abundant cell surface glycoproteins, such as CD8, CD43, and CD45, are undersialylated, thus exposing terminal O-linked Galβ1-3GalNAc, a ligand for the lectin peanut agglutinin (PNA). T-cell precursors migrate to the thymus as PNAlo CD4+ CD8+ (double negative [DN]) cells (24, 38) and make the transition to PNAhi cortical CD4+CD8+ (double positive [DP]) cells (5, 18, 19, 25–27). Upon differentiation, the DP thymocytes progress to CD4 or CD8 lineage cells, migrate to the medulla, and once again become PNAlo.

The extent of terminal Galβ1-3GalNAc exposure inversely correlates with the expression of ST3Gal-I, a Galβ1-3GalNAc-specific α2,3 sialyltransferase that is expressed primarily in medullary but not cortical thymocytes (3, 10). Upon expression of ST3Gal-I, Galβ1-3GalNAc becomes sialylated, preventing PNA binding on these cells (23). Additionally, T cells become increasingly sialylated on N-linked Galβ1-4GlcNAc as they transit from DP to single-positive (SP) cells (36). This latter sialylation is thought to involve multiple sialyltransferases (7, 35).

Naive PNAlo T cells once again become PNAhi upon mito-

gen- or antigen-mediated activation (8, 30). Effector T cells reveal terminal Galβ1-3GalNAc, possibly through the action of endogenous sialidases (8). The deletion of ST3Gal-I causes all T cells to remain PNA positive and thus undersialylated on several O-linked glycoproteins. The phenotypic effect of an ST3Gal-I deficiency was a loss of CD8 T cells in the peripheral lymphoid organs via apoptosis (23). The conclusion from these studies was that regulated sialylation plays a role in the homeostatic maintenance of CD8 T cells.

Mouse macrophage galactose- and N-acetylgalactosamine-specific C-type lectin (mMGL) is a macrophage-specific, calcium-dependent C-type lectin whose carbohydrate recognition domain has been shown to have high affinity for glycoproteins bearing terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) sugars (39). This lectin is also known as the macrophage asialoglycoprotein-binding protein by the group that cloned the gene from the rat (12). mMGL binding is inhibited by sialylation (39). It is expressed on a subpopulation of macrophages present in most tissues (20), and it has been implicated in macrophage tumoricidal ability, phagocytosis, and endocytosis (11, 15). mMGL expression is also upregulated during cardiac allograft rejection (28). Currently, the physiological role of mMGL remains uncertain.

Based on the expression of mMGL in the thymus and peripheral lymphoid organs and the existence of cells bearing potential ligands for this terminal Gal/GalNAc-specific lectin, we examined the role of mMGL-bearing cells in the regulation
and turnover of lymphocytes during development and activation. In this report we describe the generation of mice that are deficient for mMGL. An analysis of these mice revealed that the loss of mMGL did not affect lymphoid differentiation or immune function. Further, red blood cell turnover and life span are minimally affected. We also show that mMGL is not the only Gal/GalNAc-specific lectin expressed by mouse macrophages, and its inhibition does not substantially complement the ST3Gal-I deficiency. We conclude from these studies that mMGL plays a role in T-cell and erythrocyte homeostasis but that there are other macrophage lectins with redundant or overlapping functions.

MATERIALS AND METHODS

Flow cytometry. Cells were labeled with the following monoclonal antibodies and reagents: anti-CD4-phycocerythrin (PE), anti-CD8-TC (CalTag), anti-CD5-fluorescein isothiocyanate (FITC), anti-CD3-FITC, anti-heat-stable antigen-biotin, anti-CD44-PE, anti-CD25-biotin or -FITC, anti-CD62L-PE (all from Pharmingen), PNA-FITC, and Environa cronol/d agglutinin-biotin (Sigma Chemical Co., St. Louis, Mo.). Apoptotic cells were detected with annexin V-FITC (CalTag), or terminal deoxynucleotidyltransferase-dUTP-biotin nick-end labeling (Boehringer Mannheim). Samples were analyzed with a FACSFlan or FACS caliber (Becton Dickinson) and CellQuest software.

Genomic mapping and knockout construct. Exons 2 and 3 encoding the translational start site, cytoplasmic domain, and the transmembrane domain of mMGL were mapped from genomic clones isolated from a strain 129SvJ library (Stratagene, La Jolla, Calif.). The probe used was a mouse full-length mMGL cDNA isolated from a subtractive hybridization experiment and identified by sequence as previously published (3). These exons were replaced with the pPGK-neopA cassette (32), resulting in a targeting construct consisting of a 1.5-kb and a 4-kb arm to mediate homologous recombination. The construct was transfected into R1 embryonic stem (ES) cells (129 strain), and 700 G418-resistant colonies were screened for homologous recombinants. One clone, H1, was identified and injected into C57BL/6 blastocysts. Male mice obviously chimeric by coat color were crossed to C57BL/6 females to obtain F1 heterozygotes, which were then incrossed to obtain F2 mice homozygous for the deficient mMGL allele.

Immunohistochemistry. Tissues were collected from mice, frozen in OCT (VWR Scientific), and kept at −70°C until sectioned on a cryostat. Sections were air-dried fixed, washed in Tris-buffered saline, and blocked with 2% bovine serum albumin. Biotinylated and unbiotinylated polyclonal antibodies carrying multiple copies of Galp1-3GalNAc and Galna1-3GalNAc were purchased from Glyco- tech (Rockville, Md.). Antirat 13-glycoprotein (AFGP; Sigma Chemical Co.) was biotinylated with a biotinylation kit (Sigma Chemical Co.). Rat anti-mouse mMGL monoclonal antibody LOM14 (13) was prepared as previously described. Biotinylated anti-Mac-1 and FITC-conjugated anti-Mac-1 were purchased from BD Pharmingen.

Sections were incubated with primary reagents at room temperature for at least 1 h, washed, and incubated for 30 min with secondary goat anti-rat alkaline phosphatase (Jackson Immunochemicals). Sections were then developed with alkaline phosphatase substrate and Vector Blue, and nuclei were counterstained with Nuclear Fast Red (Vector Labs, Burlingame, Calif.). Alternatively, primary biotinylated reagents were developed with fluorescently tagged streptavidin or streptavidin-alkaline phosphatase.

Fibroblasts expressing mMGL. Full-length mMGL cDNA was subcloned into pcDNA3 (Invitrogen, Carlsbad, Calif.) and transfected into 3T6 fibroblasts with Polybrene as described before (21). G418-resistant clones were tested for mMGL expression with flow cytometry and Northern analysis. Positive clones were subcloned by limiting dilution. Transfected fibroblasts were seeded into 24-well plates at 105 cells/well overnight.

Peritoneal macrophages. Littermates aged 4 to 8 months were challenged with 1 ml of 3% thioglycollate intraperitoneally, and 4 days later peritoneal cells were isolated by lavage with 10 ml of cold Hanks’ balanced salt solution. Cells were washed, counted, and stained for Mac-1. Cells were resuspended in RPMI medium, seeded with 105 Mac-1 cells to form monolayers, and allowed to adhere to wells for 2 to 4 h. Nonadherent cells were vigorously washed with medium.

In vitro coculture. Thymocytes were explanted from C57BL/6 mice and cultured as described above. Thymocytes (4 × 106 to 5 × 106) were added to triplicate wells containing monolayers of macrophages or fibroblasts in 1 ml of medium for 16 to 18 h. After vigorous washing, 0.2 ml from each well was stained, counted, and analyzed by flow cytometry to determine live cell recovery. Recovery was calculated by multiplying the fraction of nonapoptotic cells (annexin V−) of a specific subset by the total number of cells recovered.

Cytotoxic T lymphocyte (CTL) assays. Cytotoxic T lymphocytes (CD8) were prepared as previously described (23). Briefly, mice were injected with 2 × 106 P815 tumor cells intraperitoneally. On day 10, spleens and mesenteric lymph nodes were isolated from mice, and lymphocytes were counted. Lymphocytes were added to 96-well V-bottomed plates containing 51Cr-labeled specific target cells (P815) or non-specific targets (EL-4) at various effector-to-target cell ratios. Cells were incubated for 4 h with targets, and 51Cr release was measured.

RESULTS

Generation of mMGL−/− mice. To understand the physiological role of mMGL in vivo, we targeted mMGL for germ line deletion in mice. Since mMGL is a type II transmembrane protein, we mapped the N-terminal transmembrane domain and targeted exons 2 and 3 for replacement with a neomycin resistance cassette with the vector pPGKneo (Fig. 1A). Homologous recombinants in ES cells could be identified by a 12-kb HindIII recombinant fragment, compared to a 10.5-kb endogenous fragment when probed with an upstream genomic probe. Of 700 G418-resistant ES clones examined by Southern blot analysis, one clone revealed the expected recombinant allele, and this clone was injected into blastocysts.
The resulting chimeric mice passed the deficient allele to the first-generation progeny (Fig. 1B). Homozygous deficient mice were deficient for mMGL by Northern (Fig. 1C) as well as by reverse transcription-PCR analysis (data not shown).

**mMGL expression.** In order to verify the absence of mMGL expression in mMGL\(^{-/-}\) mice and further characterize mMGL expression in different tissues, immunohistochemistry was carried out with anti-mMGL monoclonal antibody (LOM14). Figure 2A depicts the staining from a cytospin of peritoneal exudate cells. As shown, a large percentage of peritoneal exudate cells from wild-type mice were strongly mMGL positive. The staining of peritoneal exudate cells from mMGL\(^{-/-}\) mice was greatly diminished, although, with purified antibody, we did detect residual staining over the rat immunoglobulin background.

We also compared the expression of mMGL to that of Mac-1 in thymus, spleen, lymph node, skin, and lung from wild-type and mMGL-deficient mice. In the thymus, we found medullary staining in the wild-type mouse that was again reduced in the thymuses from mMGL\(^{-/-}\) mice (Fig. 2B). This pattern of medullary staining is intriguing because the thymo-
cytes bearing potential ligands for mMGL, namely, unsialy-
ated O-linked Gal\textsubscript{1-3}GalNAc, are located in the cortex,
whereas cells bearing this Gal/GalNAc receptor are segregated
in the medulla. In the spleen of wild-type mice, we found
sparse mMGL staining compared with Mac-1 (Fig. 2C), similar
to the staining found in liver (not shown). In contrast, mMGL
staining in skin (Fig. 2D) and lymph nodes (Fig. 2E) was at
least as frequent as Mac-1 staining. In the skin, abundant
staining was seen in the dermis, and in the lymph node there
was also abundant staining in the extrafollicular paracortex.
These results indicate that mMGL is differentially expressed in
Mac-1\(^+\) cells. It is definitely expressed on peritoneal macro-
phages; however, expression elsewhere is consistent with a
subpopulation of macrophages or mature dendritic cells. While
the antibody staining revealed by LOM14 is diminished in all
tissues from \(mMGL^{-/-}\) mice, the possibility remains that there
exists another cross-reactive mMGL-like molecule.

Normal lymphoid development and homeostasis in
\(mMGL^{-/-}\) mice. We examined \(mMGL\)-deficient mice for lymp-
phoid development. Our initial hypothesis was that medullary
mMGL-expressing macrophages might regulate the develop-
mental transition that occurs from the cortical, undersialylated
immature thymocytes to medullary, fully sialylated mature T
cells. This process can be monitored by analyzing thymocytes
stained with PNA to detect O-linked terminal Gal-GalNAc and
staining for CD4 and CD8 to detect the major thymic
subpopulations (Fig. 3A). Thymocytes were separately stained
with \(E.\ cristagalli\) agglutinin, which detects the terminal galac-
tose present on N-linked branched glycoproteins (Fig. 3A).
With either of these lectins, we found that undersialylated
thymocytes in wild-type mice were mainly CD4\(^+\)CD8\(^{-}\), the
population found in the cortex, whereas the sialylated thymo-
cytes were either CD4\(^+\)CD8\(^{-}\) (CD4SP) or CD4\(^-\)CD8\(^+\)
(CD8SP), the mature populations found in the medulla.

We next sought to determine whether the absence of
mMGL-bearing macrophages would result in an altered cellu-
larity within the thymus. Examination of thymuses from
\(mMGL^{+/+}\) and \(mMGL^{-/-}\) mice revealed that T-cell develop-
ment appears normal in mMGL-deficient mice, with thymocytes having similar subpopulations of CD4+ CD8+(CD4SP), CD4+ CD8+(CD8SP), and CD4+ CD8+(DP) cells (Fig. 3B). The number of PNA-high thymocytes in each of the subsets was also determined. The data indicate that there is no significant increase in PNAhi thymocytes in the mature CD4SP and CD8SP subsets (Fig. 3C). Likewise, development was normal as detected by surface expression of CD3, CD5, and heat-stable antigen (data not shown). Further, although variable, the rate of death appeared to be unaltered as measured by staining for apoptotic markers with annexin V, DiOC6, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (data not shown).

The thymus size of mMGL-deficient mice compared to heterozygous littermates seemed slightly increased in mice aged 8 to 16 weeks (9.8 ± 4.5) x 107 cells, n = 27 [−/−] versus 8.4 ± 3.6 x 107 cells, n = 33 [+/+]), but due to the variability within each group, this difference was not statistically significant (P > 0.05, Student’s t test, unpaired). B-cell expression of B220 was similar among wild-type and mMGL null mice, and B-cell proliferation to anti-immunoglobulin M and lipopolysaccharide in vitro was normal (data not shown). We conclude from these data that T-cell development is grossly unaltered and that expression of mMGL is not required for normal T- or B-cell development.

We also studied the function of mMGL with respect to the induction of apoptosis in Gal/GalNAc-exposed CD4+ CD8+ thymocytes. In the first set of experiments, we showed that fibroblasts transfected with mMGL would result in cell loss of CD4+ CD8+ (cortical) but not CD4SP or CD8SP (medullary) thymocytes (Fig. 3D). We then sought to determine whether elicited peritoneal macrophages would mediate the loss of thymocytes in an mMGL-dependent manner. Measuring cell recovery, viability, and apoptotic indices, we found that macrophages do have a substantial effect on the recovery of thymocytes, but after extensive investigation, including numerous separate trials, we did not find a significant difference between macrophages from wild-type and mMGL-deficient mice (data not shown). Thus, despite the ability of mMGL transfectants to mediate thymocyte cell death in vitro and the demonstrated large amounts of mMGL on peritoneal macrophages (Fig. 2A), there was no indication that mMGL expression was required for thymocyte cell death.

mMGL-deficient mice were also tested for T-cell responses by measuring the cytotoxic T-cell response to major histocompatibility-disparate tumor cells. P815 tumor cells were injected intraperitoneally into mMGL+/+ and mMGL−/− mice. On day 10 of the response, CTL specific lysis was measured ex vivo along with the expansion of CD8 T cells. The cytotoxic T-cell responses of mMGL+/+ and mMGL−/− mice were similar (Fig. 4A). Similar expansion of CD8 T cells was also observed (Fig. 4B). Both mMGL+/+ and mMGL−/− T cells exhibited the expression of activation markers, becoming CD44hi, CD62Llo, and PNAhi (data not shown). In addition, we measured the proportion of apoptotic T cells as measured by annexin V during the time course of a T-cell response in vivo and again found no significant differences in mice lacking mMGL on day 10 (Fig. 4C), day 12, or day 17 (data not shown). These results indicate that CD8 T-cell responses do not rely on mMGL for activation, effector function, or turnover of activated T cells.

Elevated red blood cell counts but similar life span and turnover. Mice were also subjected to extensive hematologic analysis, blood coagulation, and blood chemistry tests. Only measures of erythrocyte content showed a statistically significant deviation from wild-type values. As shown in Table 1, red blood cell counts, hemoglobin, hematocrit, and mean corpuscular volume were all slightly elevated in mMGL-deficient mice. This was of potential interest because one model of erythrocyte turnover is that erythrocytes lose sialic acid as a consequence of aging, and it is possible that such aged erythrocytes would be scavenged by macrophages present in the spleen and liver (9, 14, 34). While the mean differences noted were statistically significant, the mMGL−/− values still fell within the normal range for mice. In addition, an analysis of erythrocyte life span in vivo was carried out on mMGL+/+ and
mMGL 

Complementation of ST3Gal-I deficiency. In mice lacking ST3Gal-I (siat4a), there is a profound loss of CD8 T cells in the periphery (23). In these mice, there is enhanced core 2 glycosylation, revealed by the antibody 1B11, and enhanced PNA binding. Moreover, cross-linking with 1B11 on CD8 T cells from these mice induced apoptosis (23). We considered the possibility that a lack of ST3Gal-I revealed an unsialylated 1-3GalNAc disaccharide. As shown in Fig. 5, there were approximately 11% CD8 T cells at all ages in double null mice. The difference between mMGL and ST3Gal-I deficient mice could be a subpopulation of macrophages or dendritic cells. Similar staining results in the thymus were found with a biotinylated polyacrylamide-based polymer of Galβ1-3GalNAc (Galβ1-3GalNAc-PAA) (data not shown).

To determine whether the lectin was present on macrophages, spleen sections were stained with biotinylated Galβ1-3GalNAc-PAA or biotinylated anti-Mac-1. Figure 7C-E shows specific binding of undersialylated molecules and induce apoptosis. Under such circumstances, a deficiency in mMGL would be predicted to complement the loss of CD8 T cells in ST3Gal-I deficient mice.

Mice were crossed to produce ST3Gal-I 

Evidence for multiple Galβ1-3GalNAc lectins expressed on macrophages. As a probe to examine Gal/GalNAc lectins within lymphoid tissues, we used a biotinylated mucin known as AFGP, a highly glycosylated polypeptide containing multiple O-linked Galβ1-3GalNAc disaccharides. As shown in Fig. 7A and B, AFGP bound to cells located in the medulla of the thymus (compared with the streptavidin control). To show the specificity of this binding, serial sections of the thymus were stained with AFGP-biotin and competed with Galβ1-3GalNAc or Galα1-3GalNAc. As shown in Fig. 7C-E, there was a specific competition with Galβ1-3GalNAc compared with Galα1-3GalNAc. Similar staining results in the thymus were found with a biotinylated polyacrylamide-based polymer of Galβ1-3GalNAc (Galβ1-3GalNAc-PAA) (data not shown).

To determine whether the lectin was present on macrophages, spleen sections were stained with biotinylated Galβ1-3GalNAc-PAA or biotinylated anti-Mac-1, followed by alkaline phosphatase-labeled streptavidin (Fig. 8A). Similar to anti-mMGL, staining with the Gal/GalNAc polymer was sparse but definitely positive in the spleen compared with anti-Mac-1. To determine whether this staining was dependent on mMGL, sections from an mMGL 

<table>
<thead>
<tr>
<th>Parameter* (U)</th>
<th>mMGL−/+ (n = 11)</th>
<th>mMGL+/− (n = 10)</th>
<th>mMGL−/− (n = 16)</th>
<th>t test</th>
<th>Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocytes (cells/μl)</td>
<td>7,726.6 (697.67)</td>
<td>8,260.0 (848.83)</td>
<td>8,830.0 (730.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>8.1 (2.02)</td>
<td>11.7 (1.55)</td>
<td>9.6 (1.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>89.1 (2.39)</td>
<td>83.2 (1.64)</td>
<td>87.1 (1.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td>0.4 (0.18)</td>
<td>1.4 (0.24)</td>
<td>0.8 (0.21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>0.0 (0.00)</td>
<td>0.3 (0.12)</td>
<td>0.2 (0.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basophils (%)</td>
<td>2.4 (0.42)</td>
<td>3.3 (0.25)</td>
<td>2.2 (0.22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocytes (m/ml)</td>
<td>9.8 (0.15)</td>
<td>9.9 (0.13)</td>
<td>10.2 (0.09)</td>
<td>0.044</td>
<td>+3.5</td>
</tr>
<tr>
<td>Hemoglobin (g/liter)</td>
<td>15.2 (0.16)</td>
<td>15.4 (0.18)</td>
<td>15.8 (0.12)</td>
<td>0.009</td>
<td>+3.8</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>47.7 (0.52)</td>
<td>48.8 (0.54)</td>
<td>50.6 (0.41)</td>
<td>0.001</td>
<td>+6.0</td>
</tr>
<tr>
<td>Platelets (10^3/μl)</td>
<td>820.3 (48.4)</td>
<td>861.1 (55.8)</td>
<td>928.8 (29.7)</td>
<td>0.054</td>
<td>+13.2</td>
</tr>
<tr>
<td>MPV (fl)</td>
<td>7.0 (0.17)</td>
<td>7.1 (0.14)</td>
<td>7.0 (0.09)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parameter* (U)</td>
<td>mMGL−/+ (n = 11)</td>
<td>mMGL+/− (n = 10)</td>
<td>mMGL−/− (n = 16)</td>
<td>t test</td>
<td>Change (%)</td>
</tr>
<tr>
<td>Leukocytes (cells/μl)</td>
<td>7,726.6 (697.67)</td>
<td>8,260.0 (848.83)</td>
<td>8,830.0 (730.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>8.1 (2.02)</td>
<td>11.7 (1.55)</td>
<td>9.6 (1.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>89.1 (2.39)</td>
<td>83.2 (1.64)</td>
<td>87.1 (1.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td>0.4 (0.18)</td>
<td>1.4 (0.24)</td>
<td>0.8 (0.21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>0.0 (0.00)</td>
<td>0.3 (0.12)</td>
<td>0.2 (0.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basophils (%)</td>
<td>2.4 (0.42)</td>
<td>3.3 (0.25)</td>
<td>2.2 (0.22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocytes (m/ml)</td>
<td>9.8 (0.15)</td>
<td>9.9 (0.13)</td>
<td>10.2 (0.09)</td>
<td>0.044</td>
<td>+3.5</td>
</tr>
<tr>
<td>Hemoglobin (g/liter)</td>
<td>15.2 (0.16)</td>
<td>15.4 (0.18)</td>
<td>15.8 (0.12)</td>
<td>0.009</td>
<td>+3.8</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>47.7 (0.52)</td>
<td>48.8 (0.54)</td>
<td>50.6 (0.41)</td>
<td>0.001</td>
<td>+6.0</td>
</tr>
<tr>
<td>Platelets (10^3/μl)</td>
<td>820.3 (48.4)</td>
<td>861.1 (55.8)</td>
<td>928.8 (29.7)</td>
<td>0.054</td>
<td>+13.2</td>
</tr>
<tr>
<td>MPV (fl)</td>
<td>7.0 (0.17)</td>
<td>7.1 (0.14)</td>
<td>7.0 (0.09)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Data for each test are listed with the standard error of the mean in parentheses.

**M**C, mean cell volume; **MCH**, mean cell hemoglobin concentration; **RDW**, red cell distribution width; **MPV**, mean platelet volume.

**DISCUSSION**

In this report we have described the production and characterization of mice deficient in the known macrophage galactose lectin mMGL. With these mice, we addressed three questions related to a potential role for mMGL in the recognition of cell surface structures regulated by differential sialylation. First, does mMGL regulate the maturation and progression of undersialylated, cortical, CD4+ CD8+ thymocytes? Second, does mMGL regulate the turnover of effector T cells that become undersialylated subsequent to activation? Third, does
mMGL play a role in the turnover of red blood cells that lose sialylation with age?

The development and selection of thymocytes are accompanied by a high rate of cell death, so that an estimated 98% of the thymocytes produced in the thymus die prior to emigration (31). The physiological mechanisms responsible for thymocyte cell death are almost entirely uncharacterized (37). Several receptor-ligand interactions have been proposed to participate in thymocyte death (6, 16, 17, 22), but there are few examples of targeted deletions that result in thymus hyperplasia (33). Despite the many studies on the topic, there is yet no real conceptual understanding of the signaling mechanisms that distinguish positive and negative selection of developing thymocytes. As such, we wanted to study the possibility that differential sialylation during thymus development could be recognized by an endogenous lectin as a way of regulating the emergence of mature T cells. From this and previous studies, we conclude that neither the deletion of ST3Gal-I nor the deletion of mMGL appears to have a substantial effect on T-cell development (23).

mMGL-deficient mice

The observation that activated T cells lose sialylation and following expansion show significant apoptosis prompted us to consider the possibility that an endogenous lectin could induce death based on cross-linking of undersialylated molecules. This mechanism would be consistent with the loss of CD8 T cells in ST3Gal-I-deficient mice and the delay in death of antigen-specific effector CD8 T cells in CD43−/− mice (Onami et al., unpublished data). We saw no differences in CD8 T cell numbers for mMGL−/− versus mMGL+/+ mice following activation in vivo and similar numbers of apoptotic CD8 T cells in

FIG. 5. Erythrocyte (RBC) turnover in mMGL+/+ and mMGL−/− mice. Mean life span of red blood cells was determined in (A) mMGL+/+ and (B) mMGL−/− mice after biotinylation in vivo. The mean erythrocyte life span was 36.67 days in mMGL+/+ mice, versus 37.27 days in mMGL−/− mice.

FIG. 6. Effect of mMGL deficiency in ST3Gal-I-deficient mice. ST3Gal-I mice were crossed to mMGL-deficient mice to examine the role of mMGL in the CD8 T-cell loss in ST3Gal-I-deficient mice. Solid squares represent ST3Gal-I+/+ mice, which show normal CD8 T-cell numbers in the peripheral blood lymphocytes (PBL). Solid circles represent ST3Gal-I−/− mMGL−/− mice, which show decreased numbers of CD8 T cells. Open circles show doubly deficient mice. (Top) Female doubly deficient mice show a trend of increased CD8 T-cell numbers compared to ST3Gal-I-deficient mice, reaching statistical significance in female mice aged 3 and 5 weeks. (Bottom) Male mice showed no statistically significant changes.
these mice as well. To determine whether an mMGL gene inhibition could complement the targeted \(ST3Gal-I\) deficiency in the loss of CD8 T cells, we produced mice deficient in both genes. As shown, although there appeared to be a tendency toward higher numbers of CD8 T cells in the mice lacking \(mMGL\), \(mMGL^{-/-} ST3Gal-I^{-/-}\) mice still showed a profound CD8 T-cell deficiency. Therefore, we conclude that mMGL cross-linking of undersialylated cell surface molecules is not the predominant mechanism of cell loss in \(ST3Gal-I^{-/-}\) mice.

In addition to lymphocytes, erythrocytes undergo differential sialylation. Experiments show that sialic acids are lost as eryth-
erythrocytes undergo senescence (2, 4, 14). The role of sialic acids in erythrocyte senescence is not understood, but one possibility is that it constitutes one of the signals that target aged erythrocytes for destruction (9). We considered the possibility that mMGL-bearing macrophages could recognize the undersialylated erythrocytes and execute their engulfment. There does appear to be a difference in erythrocyte numbers in mMGL mice (Table 1), but the biological significance is difficult to discern. We did not find a statistically significant difference in turnover rates, leading us to believe that the increases seen in erythrocytes in mMGL mice may be explained by other indirect effects. Moreover, mMGL expression is not abundant in the spleen and liver, where erythrocyte turnover takes place after desialylation.

With AFGP as a probe, we identified an additional macrophage lectin(s) or lectin-like activity that is specific for Galb1-3GalNAc (4, 5). Involvement of mMGL. Binding of this lectin to its ligand is not affected by EDTA, suggesting that binding is not calcium dependent, and thus it is not a C-type lectin. In future studies, this lectin can be characterized further by purifying galactose-specific binding proteins with cell lysates derived from mMGL null mice. We propose that this lectin may play a functionally redundant role to mMGL and conclude that the biological significance is difficult to discern. We did not analyze the distribution of a mouse macrophage C-type lectin. Glycobiology 1:137–146.


Williams, O., and H. J. Brady. 2001. The role of molecules that mediate leukocyte differentiation and malignancy. Glycobiology 11:196–204.
ERRATUM

Generation of Mice Deficient for Macrophage Galactose- and N-Acetylgalactosamine-Specific Lectin: Limited Role in Lymphoid and Erythroid Homeostasis and Evidence for Multiple Lectins

Thandi M. Onami, Meei-Yun Lin, Dawne M. Page, Shirley A. Reynolds, Carol D. Katayama, Jamey D. Marth, Tatsuro Irimura, Ajit Varki, Nissi Varki, and Stephen Hedrick

Molecular Biology Section, Division of Biology, Cancer Center, Howard Hughes Medical Institute, Department of Cellular and Molecular Medicine, Department of Medicine, and Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California 92093, and Laboratory of Cancer Biology, University of Tokyo, Tokyo 113-8657, Japan

Volume 22, no. 14, p. 5173–5181, 2002. Page 5180, the legend to Fig. 7 should appear as shown below.

FIG. 7. Identification of Gal/GalNAc specific lectin(s) distinct from mMGL. (A) Streptavidin binding alone. (B) Biotinylated AFGP probe and streptavidin-alkaline phosphatase. (C to E) Serial sections were probed with AFGP-SA only (C), Galβ1-3GalNAc plus AFGP-SA (D), and Galα1-3GalNAc plus AFGP-SA (E). Binding was specific as it could be blocked by previous incubation with Galβ1-3GalNAc but not with Galα1-3GalNAc.